Rigel Pharmaceuticals, Inc. (RIGL)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Raul R. Rodriguez | President, CEO & Director | 1.17M | -- | 1961 |
| Mr. Dean L. Schorno CPA | Executive VP & CFO | 736.72k | -- | 1963 |
| Mr. Raymond J. Furey J.D. | Executive VP, General Counsel & Corporate Secretary | 683k | -- | 1968 |
| Mr. David A. Santos | Executive VP & Chief Commercial Officer | 737.18k | -- | 1963 |
| Ms. Julie Patel | Senior VP of Human Resources | -- | -- | -- |
| Dr. Esteban S. Masuda | Executive Vice President of Research | 537.21k | -- | 1962 |
| Mr. Joseph Lasaga | Executive VP & Chief Business Officer | -- | -- | 1975 |
| Dr. Lisa Rojkjaer M.D. | Executive VP & Chief Medical Officer | -- | -- | 1966 |
| Mr. Tarek Sallam | Vice President of Marketing | -- | -- | -- |
Rigel Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 147
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, as well as for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral IRAK1/4 Inhibitor, which is in Phase 1b clinical trials for the treatment of hematology-oncology, autoimmune, and inflammatory diseases; and a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, the company has product candidates in clinical development with partners BerGenBio ASA and Daiichi Sankyo. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of REZLIDHIA (Olutasidenib) in acute myeloid leukemia (AML) and other hematologic cancers. The company was incorporated in 1996 and is headquartered in South San Francisco, California.
Corporate Governance
Recent Events
- Apr 12, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Apr 10, 2024ARS: Annual Report to ShareholdersSee Full Filing
- Mar 29, 2024PRE 14A: Proxy StatementsSee Full Filing
- Mar 05, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 22, 20248-K: Corporate Changes & Voting MattersSee Full Filing